Opinion|Videos|November 15, 2024

Unmet Needs for Transplant-Eligible NDMM

Panelists discuss how pharmacists can address remaining unmet needs and challenges in optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), including areas such as managing complex drug interactions, improving medication adherence, mitigating treatment-related toxicities, streamlining transitions of care, and enhancing patient education and support throughout the treatment journey.

Video content above is prompted by the following:

  • What are remaining unmet needs or challenges you see around optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma that pharmacists can address?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME